Group 1 - On January 9, Awei Technology executed a block trade of 120,000 shares, with a transaction amount of 3.0036 million yuan, accounting for 6.46% of the total trading volume for that day [1] - The transaction price was 25.03 yuan, which represents a discount of 4.5% compared to the market closing price of 26.21 yuan [1][2] - The buying brokerage for the transaction was identified as "Duoduo," while the selling brokerage was noted as "190" [2]

Core Viewpoint - The company has received a scientific and technological achievement award from the Hubei Provincial Government for its project on "Key Technological Innovations and Clinical Applications of Molecular Diagnosis of Acute Leukemia" [1] Group 1: Project Details - Project Name: Key Technological Innovations and Clinical Applications of Molecular Diagnosis of Acute Leukemia [1] - Award: Second Prize of the 2025 Hubei Provincial Scientific and Technological Progress Award [1] - Main Contributors: A list of contributors including Zhou Fuling, Lei Cheng, and others [1] - Collaborating Institutions: Wuhan University, Shanghai Aisai Medical Technology Co., Ltd., Wuhan Kanglu Biological Technology Co., Ltd., Shanghai Jiao Tong University, and the company [1] - The project addresses four major clinical challenges in acute leukemia diagnosis and treatment [1] Group 2: Technological Innovations - The project has developed a comprehensive diagnostic technology system that integrates molecular mechanisms, sampling tools, diagnostic platforms, and clinical applications [1] - It reveals the oxidative stress mechanism driving malignant proliferation of leukemia stem cells through the "ROS-JAB1-TRX" pathway [1] - Innovations include the development of a painless puncture needle and a cryopreservation system, overcoming challenges in sample collection and viability [1] - The project has established a high-reproducibility PDX model and developed gene testing technologies such as EasyCatch and CoHIT, creating a promotable molecular diagnostic process [1] Group 3: Impact on the Company - The award is a recognition of the company's technological innovation and research capabilities [1] - The company plans to increase its research efforts and enhance its core competitiveness through continued technological innovation [1][2]

Core Viewpoint - The company, Awei Technology Co., Ltd., has been awarded the Second Prize of the Hubei Provincial Science and Technology Progress Award for its project on "Key Technological Innovations and Clinical Applications of Molecular Diagnosis of Acute Leukemia" [1][2]. Group 1: Project Details - The awarded project addresses four major clinical challenges in acute leukemia: early identification difficulties, narrow treatment windows, delayed classification, and high dependence on continuous monitoring [1]. - The project has developed an integrated diagnostic technology system that includes molecular mechanisms, sampling tools, diagnostic platforms, and clinical applications [1]. - Key innovations include the revelation of the "ROS-JAB1-TRX" pathway driving malignant proliferation of leukemia stem cells, and the development of a painless puncture needle and preservation liquid system to overcome challenges in sample collection [1]. Group 2: Impact on the Company - The award is a recognition of the company's technological innovation and research capabilities, which is expected to enhance its core competitiveness [2]. - The company plans to increase its research efforts to further improve its technological innovation capabilities [2]. - While the award is anticipated to have a positive impact on the company's future development, it is noted that there will be no significant immediate effect on the company's financial performance [2].

证券代码：688067 证券简称：爱威科技 公告编号：2026-002 的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司 爱威科技股份有限公司（以下简称 "公司"）近日收到湖北省人民政府颁 发的科学技术奖励证书，公司参与完成的"急性白血病骨髓分子诊断关键技术创 新及临床应用"项目荣获 2025 年度湖北省科学技术进步奖二等奖，相关情况如 下： 关于获得湖北省科学技术进步奖二等奖 一、基本情况 项目名称：急性白血病骨髓分子诊断关键技术创新及临床应用 奖项名称：2025 年度湖北省科学技术进步奖二等奖 主要完成人：周芙玲、雷诚、孙洪荣、李雪梅、刘晓燕、吴金娴、童振、沈 辉、喻亚兰、张沪寅、孟宪梅、李段滕川、刘银、黄婷婷、潘宇哲 主要完成单位：武汉大学、上海埃斯埃医疗技术有限公司、武汉康录生物技 术股份有限公司、上海交通大学、爱威科技股份有限公司 "急性白血病骨髓分子诊断关键技术创新及临床应用"项目针对急性白血病 "早期识别难、治疗窗口窄、分型滞后、全程监测依赖度高"等四大临床难题， 首创" ...

Core Viewpoint - Aivi Technology (688067.SH) has received a scientific and technological achievement award from the Hubei Provincial People's Government for its project on "Key Technological Innovations and Clinical Applications of Molecular Diagnosis for Acute Leukemia" which won the second prize of the 2025 Hubei Provincial Science and Technology Progress Award [1] Group 1 - The award recognizes the company's technological innovation and research capabilities [1] - The company plans to increase its research efforts to enhance its technological innovation capabilities [1] - The recognition is expected to further strengthen the company's core competitiveness [1]

Core Viewpoint - Aivi Technology (688067.SH) has received a scientific and technological achievement award from the Hubei Provincial People's Government for its project on "Key Technological Innovations and Clinical Applications of Molecular Diagnosis for Acute Leukemia," which won the second prize of the 2025 Hubei Provincial Science and Technology Progress Award [1] Group 1 - The award recognizes the company's technological innovation and research capabilities [1] - The company plans to increase its research efforts to enhance its technological innovation capabilities [1] - The recognition is expected to further strengthen the company's core competitiveness [1]

Group 1 - The company, Awei Technology Co., Ltd., and its subsidiary Hunan Awei Medical Technology Co., Ltd. obtained 11 domestic patent certificates from October 1, 2025, to December 31, 2025, including 5 invention patents, 1 utility model patent, and 5 design patents [1] - The company also acquired 1 overseas patent and 1 medical device registration certificate, which reflects the company's core technology and enhances its intellectual property protection system [1] - The acquisition of the medical device registration certificate will enrich the company's product variety, meet market demand, and strengthen its core competitiveness [2]

Core Points - The company, Aiwei Technology Co., Ltd., has obtained 11 domestic patent certificates and 1 foreign patent certificate from October 1, 2025, to December 31, 2025, including 5 invention patents, 1 utility model patent, and 5 design patents [1][2] - The acquisition of these patents reflects the company's core technology and enhances its intellectual property protection system, promoting technological innovation and improving core competitiveness [1] - The company has also obtained a medical device registration certificate, which will enrich its product variety and meet market demand, thereby enhancing its core competitiveness [2] Patent Certificates - The company acquired 11 domestic patents, which include 5 invention patents, 1 utility model patent, and 5 design patents [1] - Additionally, the company secured 1 foreign patent, indicating its commitment to expanding its intellectual property portfolio [1] Medical Device Registration - The medical device registration certificate obtained allows the company to enter the domestic market, although the actual sales performance of the products will depend on future marketing efforts [2] - The company currently cannot predict the specific impact of these products on future revenue [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688067 证券简称：爱威科技 公告编号：2026-001 爱威科技股份有限公司 关于取得专利证书及医疗器械注册证 的自愿性披露公告 上述医疗器械注册证的取得，有利于丰富公司的产品种类，满足市场需求， 增强公司的核心竞争能力。但上述注册证的取得仅代表公司相关产品获得国内市 场准入资格，产品上市后的实销售情况取决于未来市场的推广效果，公司目前尚 无法预测上述产品对公司未来营业收入的具体影响。敬请投资者理性投资，注意 2 爱威科技股份有限公司（以下简称"爱威科技"、"公司"）及其子公司湖 南爱威医疗科技有限公司（以下简称"湖南爱威"）自 2025 年 10 月 1 日起至 2025 年 12 月 31 日 取得境内专利证书 11 项，其中发明专利 5 项、实用新型专 利 1 项、外观设计专利 5 项；取得境外专利 1 项；取得医疗器械注册证 1 项。具 体情况如下： 一、专利证书 | 序号 | 专利名称 | 专利号 | 专利权人 | 申请日期 | 专利 | 取得 | ...

重要内容提示： | 投资标的名称 | 湖南麓影科技有限公司 | | | | --- | --- | --- | --- | | 投资金额（万元） | 1,000 | | | | 投资进展情况 | 完成 | 终止 | 交易要素变更 | | | 1、本次投资完成后，麓影科技成为公司的参股公司。公 | | | | | 司依据签署的相关协议及标的公司章程行使股东权利，麓 | | | | | 影科技的具体经营管理等仍由其现有管理团队负责，本次 | | | | | 投资存在一定的公司治理及管控风险。 | | | | | 2、麓影科技成立时间较短，目前尚未有销售收入及实现 | | | | 特别风险提示 | 盈利。其核心产品高端医学影像 SPECT/CT 尚处于开发之 | | | | | 中，未来能否顺利研发成功及完成产品的医疗器械证书申 | | | | | 报存在一定的不确定性。同时后续麓影科技在实际运营中 | | | | | 还面临宏观经济及行业政策变化、经营管理、技术研发、 | | | | | 市场开发等方面的风险因素，未来经营情况存在一定的不 | | | | | 确定性，本次对外投资存在无法实现预期收益的风险。 ...